Released : November 14, 2019 07:00 RNS Number : 3429T MaxCyte, Inc. 14 November 2019 MaxCyte to Present at 2019 Jefferies London Healthcare Conference Gaithersburg, Maryland - 14 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company,
Released : November 07, 2019 07:00 RNS Number : 5671S MaxCyte, Inc. 07 November 2019 MaxCyte to Present at BIO-Europe 2019 Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces that President and
Released : November 01, 2019 13:04 RNS Number : 0228S MaxCyte, Inc. 01 November 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Gaithersburg, MD - 0 1 November 2019 : MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, announces that at
Released : October 24, 2019 07:00 RNS Number : 9395Q MaxCyte, Inc. 24 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients MCY-M11 is being evaluated in relapsed/refractory
Released : October 23, 2019 07:01 RNS Number : 8257Q MaxCyte, Inc. 23 October 2019 MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology Gaithersburg, Maryland - 23 October 2019 - MaxCyte (LSE: MXCT, MXCS), the global
Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m.
Released : October 08, 2019 07:00 RNS Number : 0594P MaxCyte, Inc. 08 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global
Released : October 07, 2019 07:00 RNS Number : 9473O MaxCyte, Inc. 07 October 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines CAMBRIDGE, Mass. , and GAITHERSBURG, Md. , October 7, 2019 - Editas Medicine, Inc.
Gaithersburg, Maryland – October 2, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today its planned participation at key upcoming industry conferences. These conferences and events will provide an opportunity for MaxCyte to showcase how the Company is driving
